December 9, 2017

Cambridge, MA — H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global Oncology Business Group, today announced that data from the company’s academic collaborations in RNA splicing biology will be presented over the next three days at the 2017 American Society of Hematology (ASH) meeting in Atlanta, GA. The presentations are part of three academic research collaborations and will detail pre-clinical studies evaluating the role of RNA splicing in cancer biology and potential approaches for therapeutic intervention.

Participating in these studies with H3 Biomedicine are Memorial Sloan Kettering Cancer Center, Cold Spring Harbor Laboratory, the University of Manchester, Institute Gustave Roussy, Université Paris-Saclay, the University of Texas, Dana Farber Cancer Institute, University of California, Center for Molecular Medicine of the Austrian Academy of Sciences, MD Anderson Cancer Center, Broad Institute, Beckman Research Institute and Harvard Medical School.

“We are grateful to the academic centers that have become a key aspect of our research efforts, and we are pleased to continue these ongoing relationships,” said Markus Warmuth, M.D., Chief Executive Officer and President of H3 Biomedicine. “We look forward to exploring the potential of our RNA splicing platform and expand our insights on how best to target the spliceosome, in order to help H3 enhance its mission to develop important new cancer drugs.”

The details of the presentations are as follows:

Title 1: Splicing Modulation Perturbs Key Survival Pathways and Sensitizes Chronic Lymphocytic Leukemia to Venetoclax Treatment
Program: Oral and Poster Abstracts
Type: Oral
Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Therapeutic Resistance in CLL
Date/Time: Saturday, December 9, 2017: 5:15 PM. Building C, Level 1, Room C101
Location: Auditorium of the Georgia World Congress Center

Title 2: Spliceosomal Dysfunction Is a Critical Mediator of IDH2 Mutant Leukemogenesis
Program: Oral and Poster Abstracts
Type: Oral
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis I
Date/Time: Sunday, December 10, 2017: 5:30 PM
Location: Building C, Level 2, C202-C204 of the Georgia World Congress Center

Title 3: 289 Dynamic BH3 Profiling to Assess the Effects of Novel Agents on Anti-Apoptotic Protein Dependence of CLL Cells
Program: Oral and Poster Abstracts
Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III
Date/Time: Monday, December 11, 2017, 6:00-8:00 p.m.
Location: Building A, Level 1, Hall A2 of the Georgia World Congress Center

“H3 is exploring the potential of targeting the spliceosome, which has become an integral part of our research and development efforts,” said Pete Smith, Ph.D., Chief Scientific Officer for H3 Biomedicine. “A critical component of our research and translational work is undertaken in strong collaboration with leading investigators and academic centers. This work will be exemplified through the presentations at the ASH meeting.”

About H3 Biomedicine Inc.

H3 Biomedicine is a Cambridge, Massachusetts-based biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and was established as a subsidiary of Eisai's U.S. pharmaceutical operation, Eisai Inc. Leveraging this collaboration with Eisai Co., Ltd., who through this partnership provides essential research funding and access to the capabilities and resources of this global pharmaceutical company, H3 Biomedicine combines long-term vision with operational independence. Using modern synthetic chemistry, chemical biology, and human genetics, H3 Biomedicine seeks to bring the next generation of cancer treatments to market with the goal of improving the lives of patients. For more information, please visit

Media Inquiries